Sponsored Links
| OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial Of Anti-Cancer Stem Cell Therapeutic OMP-59R5 |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced that patient dosing has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers. OMP-59R5 is a monoclonal antibody that binds selected Notch receptors and is the first antibody to specifically block these targets to enter human studies... Read more: Clinical Trials / Drug Trials News From Medical News Today
|